

AMICUS THERAPEUTICS INC
 Form 3
 May 30, 2007

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Schaeffer Orlov S Nicole (Last) (First) (Middle)	2. Date of Event Requiring Statement (Month/Day/Year) 05/30/2007	3. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS INC [FOLD]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) VP, HR & Leadership Devt	5. If Amendment, Date Original Filed(Month/Day/Year)
C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE (Street)				
CRANBURY, NJ 08512 (City) (State) (Zip)				
6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	12,795	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
-----------------------------------------------	-------------------------------------------------------------	--------------------------------------------------------------------------------	-----------------------------------------------	-------------------------------------------	----------------------------------------------------------

Edgar Filing: AMICUS THERAPEUTICS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	Â (1)	03/10/2015	Common Stock	10,156	\$ 0.638	D	Â
Employee Stock Option (right to buy)	Â (2)	08/01/2015	Common Stock	4,027	\$ 0.638	D	Â
Employee Stock Option (right to buy)	Â (3)	10/20/2015	Common Stock	10,000	\$ 5.33	D	Â
Employee Stock Option (right to buy)	Â (4)	02/28/2016	Common Stock	20,000	\$ 5.33	D	Â
Employee Stock Option (right to buy)	Â (5)	04/25/2017	Common Stock	23,334	\$ 13.43	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Schaeffer Orlov S Nicole C/O AMICUS THERAPEUTICS, INC. 6 CEDAR BROOK DRIVE CRANBURY,Â NJÂ 08512	Â	Â	Â VP, HR & Leadership Devt	Â

Signatures

/s/ Douglas A. Branch,
Attorney-in-fact

05/30/2007

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on March 21, 2006. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 424 shares, beginning on April 1, 2006, with the final installment of 393 shares vesting on March 1, 2009.

(2) These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on August 1, 2006. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 139 shares, beginning on September 1, 2006, with the final installment of 135 shares vesting on August 1, 2009.

(3) These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on October 20, 2006. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 209 shares, beginning on November 1, 2006, with the final installment of 185 shares vesting on October 1, 2009.

(4) These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vest on February 28, 2007. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 417 shares, beginning on March 1, 2007, with a final installment of 405 shares vesting on February 1, 2010.

Edgar Filing: AMICUS THERAPEUTICS INC - Form 3

- (5) These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, will vest on April 25, 2008. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 487 shares, beginning on May 1, 2008, with a final installment of 455 shares vesting on April 1, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.